Johnson & Johnson (JNJ) Short term Debt (2009 - 2026)
Johnson & Johnson recorded quarterly Short term Debt of $17.5 billion in Q1 2026, up 105.53% quarter-over-quarter from $8.5 billion in Q4 2025, and up 25.64% year-over-year from $13.9 billion in Q1 2025.
Johnson & Johnson's Short term Debt history runs 18 years deep, the most recent figure standing at $17.5 billion for Q1 2026.
- In Q1 2026, Short term Debt rose 25.64% year-over-year to $17.5 billion; the TTM figure through Mar 2026 stood at $17.5 billion (up 25.64% YoY), while the FY2025 annual figure was $8.5 billion, up 41.99% from the prior year.
- Short term Debt came in at $17.5 billion for Q1 2026 at Johnson & Johnson, up from $8.5 billion in the prior quarter.
- In the past five years, Short term Debt ranged from a high of $18.0 billion in Q2 2023 to a low of $3.5 billion in Q4 2023.
- A 5-year average of $8.5 billion and a median of $7.4 billion in 2025 frame the typical range for Short term Debt.
- On a YoY basis, Short term Debt climbed as much as 318.41% in 2023 and fell as far as 72.95% in 2023.
- Johnson & Johnson's Short term Debt stood at $4.4 billion in 2022, then decreased by 21.99% to $3.5 billion in 2023, then soared by 73.37% to $6.0 billion in 2024, then surged by 41.99% to $8.5 billion in 2025, then surged by 105.53% to $17.5 billion in 2026.
- According to Business Quant data, Short term Debt over the past three periods registered $17.5 billion, $8.5 billion, and $6.4 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 29, 2026 | 17.46 Bn |
| Dec 28, 2025 | 8.50 Bn |
| Sep 28, 2025 | 6.39 Bn |
| Jun 29, 2025 | 11.53 Bn |
| Mar 30, 2025 | 13.90 Bn |
| Dec 29, 2024 | 5.98 Bn |
| Sep 29, 2024 | 4.46 Bn |
| Jun 30, 2024 | 9.86 Bn |
| Mar 31, 2024 | 8.55 Bn |
| Dec 31, 2023 | 3.45 Bn |
| Oct 1, 2023 | 3.87 Bn |
| Jul 2, 2023 | 11.70 Bn |
| Apr 2, 2023 | 17.98 Bn |
| Jan 1, 2023 | 12.76 Bn |
| Oct 2, 2022 | 4.42 Bn |
| Jul 3, 2022 | 4.31 Bn |
| Apr 3, 2022 | 4.30 Bn |
| Jan 2, 2022 | 3.77 Bn |
| Oct 3, 2021 | 3.80 Bn |
| Jul 4, 2021 | 3.17 Bn |
| Apr 4, 2021 | 3.35 Bn |
| Jan 3, 2021 | 2.63 Bn |
| Sep 27, 2020 | 5.08 Bn |
| Jun 28, 2020 | 5.33 Bn |
| Mar 29, 2020 | 2.19 Bn |
| Dec 29, 2019 | 1.20 Bn |
| Sep 29, 2019 | 2.30 Bn |
| Jun 30, 2019 | 1.72 Bn |
| Mar 31, 2019 | 1.71 Bn |
| Dec 30, 2018 | 2.80 Bn |
| Sep 30, 2018 | 1.77 Bn |
| Jul 1, 2018 | 2.68 Bn |
| Apr 1, 2018 | 2.70 Bn |
| Dec 31, 2017 | 3.91 Bn |
| Oct 1, 2017 | 8.49 Bn |
| Jul 2, 2017 | 7.21 Bn |
| Apr 2, 2017 | 5.36 Bn |
| Jan 1, 2017 | 4.68 Bn |
| Oct 2, 2016 | 3.44 Bn |
| Jul 3, 2016 | 1.71 Bn |
| Apr 3, 2016 | 3.12 Bn |
| Jan 3, 2016 | 7.00 Bn |
| Sep 27, 2015 | 5.68 Bn |
| Jun 28, 2015 | 5.22 Bn |
| Mar 29, 2015 | 4.05 Bn |
| Dec 28, 2014 | 3.64 Bn |
| Sep 28, 2014 | 2.12 Bn |
| Jun 29, 2014 | 3.82 Bn |
| Mar 30, 2014 | 3.95 Bn |
| Dec 29, 2013 | 4.85 Bn |
| Sep 29, 2013 | 5.36 Bn |
| Jun 30, 2013 | 5.34 Bn |
| Mar 31, 2013 | 4.53 Bn |
| Dec 30, 2012 | 4.68 Bn |
| Sep 30, 2012 | 5.42 Bn |
| Jul 1, 2012 | 6.04 Bn |
| Apr 1, 2012 | 6.44 Bn |
| Jan 1, 2012 | 6.66 Bn |
| Oct 2, 2011 | 5.33 Bn |
| Jul 3, 2011 | 5.05 Bn |
| Apr 3, 2011 | 8.58 Bn |
| Jan 2, 2011 | 7.62 Bn |
| Oct 3, 2010 | 2.84 Bn |
| Jul 4, 2010 | 3.72 Bn |
| Apr 4, 2010 | 4.04 Bn |
| Jan 3, 2010 | 6.32 Bn |
| Sep 27, 2009 | 3.34 Bn |
| Jun 28, 2009 | 5.44 Bn |